Learn about our poster illustrating disparities in glioblastoma treatment presented at SNO, the premier neuro-oncology conference
NEWS December 2023
OurBrainBank Executive Director Kelli Duprey, board member Kate Onk, and staffer Kristi Payne attended the Society for Neuro-Oncology 28th Annual Meeting in Vancouver, November 16-19th. The SNO Annual Meeting is the world’s largest neuro-oncology conference, regularly attracting over 2600 researchers and clinician scientists from more than 40 countries. Spanning all neuro-oncology disciplines, professions, and interests, the SNO Annual Meeting is the premier forum to share knowledge and gain insights on the future of neuro-oncology research and treatment.
OurBrainBank had a poster, booth, and hosted a reception to share our work. Most notable was the acceptance and interest in our poster on health disparities in GBM.
We met with 26 other nonprofits working in brain cancer from the US, Canada, and the UK. Each organization shared their work and spoke about how we can all help one another. SNO president, Tracy Batchelor, and SNO CEO, Chaz Haynes, led the lively discussion.
We also connected with people from companies leading breakthroughs in GBM treatment and diagnosis.
- ImVax: Phase 2b trial of IGV-001 for Patients with Newly Diagnosed GBM
- Plus Therapeutics: ReSpect trial
- Orbus: Phase 1 trial of Eflornithine with GBM
- Chimerix: ACTION Study, randomized Phase 3 study on ONC201(Dordaviprone) in patients with newly diagnosed H3 K27M mutant diffuse glioma
- Telix: The Promise of PET imaging with Amino Acid Radiotracers for Brain Tumors, Phase 3
- Gamma Tile: GammaTile brachytherapy for recurrent GBM
- MRIMath: Trustworthy and explainable AI software to assist physicians in brain tumor segmentation and volumetric analysis within a few minutes
- Ivy Brain Tumor Center: promising results from a Phase 0/2 trial of Niraparib in patients with newly diagnosed glioblastoma with unmethylated MGMT
Kelli left the meeting with great enthusiasm and hope for better diagnosis tools and treatment for people living with GBM.
“We will move GBM from terminal to treatable powered by patients. Please contact us if you would like any information on the material above. Together we can be better,” said Kelli.